title: [Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer].
abstract: Cyclooxygenase-2 (Cox-2) is over-expressed in prostate cancer (PCa) and involved in its development and progression by facilitating inflammatory response, reducing cell apoptosis, increasing angiogenesis and damaging DNA oxidation. Selective Cox-2 inhibitors suppress PCa growth through various channels and therefore have a promising application value in the management of prostate cancer.
authors.affiliation: Department of Urology, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
authors.forename: Song
authors.initials: S
authors.lastname: Xu
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Gao
authors.forename: Wen-Quan
authors.initials: WQ
authors.lastname: Zhou
mesh_terms: D017209:Apoptosis; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human